Key result
Retrospective SYNERGY analysis provides no definitive clinical outcome data on early angiography timing in high-risk ACS.
Why the study?
The optimal timing of angiography for patients with acute coronary syndromes at high risk for adverse events is not known.
Key points are not available for this paper at this time.
Design
Retrospective analysis of SYNERGY trial data
Retrospective SYNERGY analysis yields no actionable timing guidance in high-risk ACS; leaves optimal strategy unresolved pending prospective trials.
Although an early invasive strategy is generally recommended for patients with acute coronary syndromes at high risk for adverse events (Journal Watch Cardiology Sep 12 2007), the optimal timing of angiography is not known. In this retrospective analysis of data from the SYNERGY trial, a manufacturer-funded study of enoxaparin versus unfractionated heparin …
No takes yet. Share an insight, caveat, or question.
Howard C. Herrmann (2008) studied this question. Early angiography timing in high-risk acute coronary syndromes was analyzed retrospectively using SYNERGY trial data, but the truncated abstract lacks specific clinical findings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: